PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025
Summary
Coronary artery disease (CAD), which precipitates acute coronary syndrome (ACS), is the most common type of cardiovascular disease (CVD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). At present, the cardiovascular (CV) drug market is well established and boasts a multitude of branded and generic drug choices to treat the major conditions associated with ACS: thrombosis (fibrinolytics, anticoagulants, and antiplatelets), hypercholesterolemia/atherosclerosis (statins and PCSK9 inhibitors), and hypertension (renin angiotensin aldosterone system (RAAS) inhibitors and beta blockers). Due to this range of sub-indications and the recent increase in disease prevalence, it is evident that ACS represents a potentially lucrative market for Big Pharma to explore.
It is estimated that sales of acute coronary syndrome (ACS) therapeutics to be approximately $7.8B across the 7MM in 2015, including the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2015 base year 10% of market share were attributed to the acute phase sales ($714M) and 90% to the chronic phase ($7.0B). By 2025, the ACS market to grow at a strong Compound Annual Growth Rate (CAGR) of 4.6%, reaching sales of $12.1B by the end of the forecast period. This is mainly attributed to the chronic phase growth, which is forecast to reflect a CAGR of 5.0%, reaching $11.4B in sales by 2025 (94% of market share).
As per Michela J. McMullan, Analyst: “At present, a large proportion of patients with clinical atherosclerotic cardiovascular disease cannot reach guideline recommended levels of LDL-C with the standard of care therapies, which leads to recurrent ACS events.
Major drivers of ACS market growth over the forecast period are the -
- Launches of the first PCSK9 inhibitors, Repatha (evolocumab) and Praluent (alirocumab), in the US (2015), EU (2015), and Japan (2016); and positive results from their cardiovascular (CV) outcomes trials.
- Launch of first-in-class lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor/ adenosine monophosphate-activated protein kinase (AMPK) activator, ETC-1002, in 2021.
- Increase in the global prevalence of ACS.
The report “PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025” provides overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
In depth, this report provides the following analysis -
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Amgen, AstraZeneca, Bristol-Myers Squibb, Cerenis Therapeutics, CSL Limited, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, (Johnson & Johnson), The Medicines Company, Merck, Pfizer, Sanofi
Highlights
Key Questions Answered
- The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?
- The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases , as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?
Key Findings
- The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
- The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.
- The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
- The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.
Scope
- Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ACS therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.